Cancer Pipeline (Bladder, Nasopharyngeal, Metastatic Prostate Cancer) H2 2015 Review Research Reports on Therapeutic Development

News provided by

Sep 09, 2015, 10:00 ET

PUNE, India, September 10, 2015 /PRNewswire/ --

RnRMarketResearch.com adds H2 2015 cancer pipeline review research reports for bladder, nasopharyngeal cancer and metastatic prostate cancer with a focus on their products and therapeutic development.

Complete report on Bladder Cancer - Pipeline Review, H2 2015 spread across 508 pages, talking about 83 companies, 100+ drug profiles and supported with 118 tables and 17 figures is now available at http://www.rnrmarketresearch.com/bladder-cancer-pipeline-review-h2-2015-market-report.html .

These cancer pipeline review reports provide comprehensive information on the therapeutic development for Bladder Cancer, Nasopharyngeal and Metastatic Prostate Cancer complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bladder Cancer, Nasopharyngeal, Metastatic Prostate Cancer and special features on late-stage and discontinued projects. Further details on each of these individual cancer pipeline review reports are available below.

Bladder Cancer - Pipeline Review, H2 2015: Companies involved in bladder cancer therapeutics development and mentioned in this research include Advaxis, Inc., Alligator Bioscience AB, Alnylam Pharmaceuticals, Inc., Altor BioScience Corporation, AndroScience Corporation, APIM Therapeutics AS, Arno Therapeutics, Inc., Ascenta Therapeutics, Inc., Astellas Pharma Inc., AstraZeneca Plc, AuraSense Therapeutics, LLC, AVEO Pharmaceuticals, Inc., AvidBiotics Corp., Bavarian Nordic A/S, Bayer AG, BioCancell Ltd, Bioncotech Therapeutics S.L., Biotest AG, cCAM Biotherapeutics Ltd., Celgene Corporation, Celldex Therapeutics, Inc., Cold Genesys, Inc., Daiichi Sankyo Company, Limited, DormaTarg, Inc., Eisai Co., Ltd., Eli Lilly and Company, EntreChem, S.L., Esperance Pharmaceuticals, Inc., Evotec AG, F. Hoffmann-La Roche Ltd., Gene Signal International SA, Genmab A/S, GlaxoSmithKline Plc, Heat Biologics, Inc., Horizon Pharma Plc, Hutchison MediPharma Limited, Idera Pharmaceuticals, Inc., Immunomedics, Inc., Immupharma Plc, ImmuRx, Inc., Ludwig Institute For Cancer Research Ltd, MacroGenics, Inc., Marina Biotech, Inc., Meabco A/S, MedImmune, LLC, Merck & Co., Inc., Millennium Pharmaceuticals, Inc., Mirati Therapeutics Inc., NuCana BioMed Limited, Omeros Corporation, Oncogenex Pharmaceuticals, Inc., Oncolytics Biotech Inc., Oncopeptides AB, Ono Pharmaceutical Co., Ltd., Optimum Therapeutics, LLC, Panacela Labs, Inc., Pfizer Inc., Pharma Mar, S.A., Polaris Pharmaceuticals, Inc., PsiOxus Therapeutics Limited, Qu Biologics Inc., Quest PharmaTech Inc., Samyang Holdings Corporation, Sanofi, Serometrix, LLC, Shionogi & Co., Ltd., Sorrento Therapeutics, Inc., Spectrum Pharmaceuticals, Inc., Stemline Therapeutics, Inc., Sumitomo Dainippon Pharma Co., Ltd., Sun Pharma Advanced Research Company Ltd., Synta Pharmaceuticals Corp., TARIS BioMedical, Inc., Telesta Therapeutics Inc., Telormedix SA, Theravectys SA, TheRyte Limited, Tolero Pharmaceuticals, Inc., Transgene SA, Vakzine Projekt Management GmbH, Vaxeal Holding SA, Viralytics Ltd. and Viventia Biotechnologies Inc. Order a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=414335 .

Metastatic Prostate Cancer - Pipeline Review, H2 2015: This is a 95 pages report that talks about companies like Actinium Pharmaceuticals, Inc., Camurus AB, Dongkook Pharmaceutical Co., Ltd., Eli Lilly and Company, EntreChem, S.L., Johnson & Johnson, MedImmune, LLC, MEI Pharma, Inc., Merck & Co., Inc., OncoMax, OXiGENE, Inc., Progenics Pharmaceuticals, Inc. and ValiRx Plc that are involved in metastatic prostate cancer therapeutics development. Drug profiles like abiraterone acetate, Actimab-P, AST-VAC-1, CADD-522, Cell Therapy to Target PSMA for Metastatic Prostate Cancer, EC-7073, HepIn-13, KGP-94, landogrozumab, leuprolide acetate, MEDI-6469, MIP-1095, MVI-118, OMRCA-01, pracinostat, Recombinant Protein for Oncology, triptorelin pamoate, Vaccine For Oncolytic Newcastle Disease Virus, VAL-201 and vorinostat are covered in this metastatic prostate cancer pipeline review report having 31 tables, 15 figures and available at http://www.rnrmarketresearch.com/metastatic-prostate-cancer-pipeline-review-h2-2015-market-report.html .

Nasopharyngeal Cancer - Pipeline Review, H2 2015: Spread across 94 pages, this nasopharyngeal cancer pipeline review report profiles drugs like abexinostat hydrochloride, azacitidine, Cell Therapy 2 for Oncology and Infectious Disease, Cell Therapy for Metastatic Nasopharyngeal Carcinoma and Colorectal Cancer, Cell Therapy for Nasopharingeal Carcinoma, Cell Therapy to Target Latent Membrane Protein-2 for Oncology, Cell Therapy to Target LMP-1 and LMP-2 for Metastatic Nasopharyngeal Carcinoma, Cell Therapy to Target LMP-1 and LMP-2 for Oncology, DC-120, Dendritic Cells + Cytokine Induced Killer Cells, EBV-nRNA, ficlatuzumab, Gene Therapy to Activate p53 for Oncology, GSK-2849330, icotinib hydrochloride, MK-2206, Monoclonal Antibody Drug Conjugate to Inhibit CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma, NEO-212, nimotuzumab, OPB-51602, RO-5203280, seliciclib, Small Molecules for Nasopharyngeal and Colon Cancers, Stem Cell Therapy for Oncology, Vaccine for EBV Associated Cancer, Vaccine for Epstein-Barr Viral Infections and Nasopharyngeal Cancer and Vaccine to Target EBV for Nasopharyngeal Carcinoma. Companies involved in nasopharyngeal cancer therapeutics development and covered in this research include Ambrx, Inc., AVEO Pharmaceuticals, Inc., BioDiem Ltd, Celgene Corporation, Cyclacel Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck & Co., Inc., Otsuka Holdings Co., Ltd., Pharmacyclics, Inc., Theravectys SA and Zhejiang BetaPharma Co., Ltd. Comprehensive table of contents and more on this research is available at http://www.rnrmarketresearch.com/nasopharyngeal-cancer-pipeline-review-h2-2015-market-report.html .

Explore more reports on the cancer therapeutics market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics .

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel: +1-888-391-5441
[email protected]

Connect with Us:

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

SOURCE RnR Market Research